PrEP Side Effects: What to Expect in the First 90 Days

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

PrEP Side Effects: What to Expect in the First 90 Days

Quick Answer: Most people on daily oral PrEP (Tenvir-EM, Truvada, Descovy, Tenof-EM and similar) experience mild and short-lived side effects in the first 30–90 days — the so-called “start-up syndrome” of nausea, headache, fatigue, or loose stools — and these clear up by the 3-month mark in over 90% of users. The two side effects that need active monitoring are renal function and bone mineral density, both of which return to baseline after stopping PrEP. Serious adverse events are rare. This guide walks through what’s normal, what isn’t, and when to escalate.

What’s in PrEP, and Why It Matters for Side Effects

The two oral PrEP regimens available globally are:

• Tenofovir disoproxil fumarate (TDF) + emtricitabine (FTC) — sold as Truvada in branded form; available as Tenvir-EM, Tenof-EM, Ricovir-EM, and Tavin-EM from WHO-GMP-certified manufacturers (Cipla, Hetero, Mylan).
• Tenofovir alafenamide (TAF) + emtricitabine (FTC) — sold as Descovy in branded form; available as Tenvir-AF.

The two regimens are virologically equivalent. The differences are in side-effect profile: TDF (Tenvir-EM family) is the older formulation and has slightly more impact on kidney function and bone density. TAF (Tenvir-AF) is newer, intracellularly activated, achieves the same antiviral concentrations at a much lower plasma dose, and is gentler on bones and kidneys — but slightly worse for cholesterol and weight. For a head-to-head comparison see our Truvada vs Descovy guide.

The “Start-Up Syndrome”: Weeks 1–4

The first month is when most side effects appear, and most of them resolve on their own.

Nausea and Stomach Upset

Nausea is the most common side effect, reported in 8–14% of PrEP users in the original iPrEx trial and in subsequent open-label cohorts. It usually begins within 3–7 days, lasts 2–4 weeks, and resolves without intervention.

What to do: Take the pill with food. Switching from morning to evening dosing helps about a third of people. Ginger, peppermint, or short-term antihistamine antiemetics can bridge the worst week if needed. Persistent nausea past week 6 is unusual and warrants a check.

Headache

About 5–10% report headaches in the first month. These are usually mild, respond to standard analgesics, and resolve without dose changes.

Fatigue and “Foggy” Feeling

Some users report a general lethargy or low mood in the first 2–3 weeks. This is more common in people who started PrEP during a period of high stress or sleep disruption (a not-uncommon time to start PrEP, e.g. ahead of a vacation). It clears within 4 weeks for most.

Loose Stools / Diarrhoea

Reported in 7–10% of users in trials. Usually mild and self-limiting. Persistent diarrhoea past 4 weeks warrants a stool culture and a check for unrelated GI infection.

Reassurance: Of the side effects above, none are predictors of long-term issues. Trial data and real-world cohorts (UK PROUD, French IPERGAY, US Demo Project) all converge on the same picture: people who push through weeks 2–4 almost always stabilise.

Weeks 5–12: What Stabilises, What to Track

Renal Function (Creatinine, eGFR)

TDF (Tenvir-EM and similar) can cause a mild, reversible decrease in glomerular filtration rate. In the iPrEx trial, mean eGFR dropped by 2–3 mL/min after 12 weeks and stabilised. The vast majority of users stay well within the normal range (≥60 mL/min/1.73 m²).

Risk factors for clinically meaningful renal effects: pre-existing chronic kidney disease (eGFR <60 at baseline), age over 50, hypertension, diabetes, and NSAID co-use. Anyone in this group is a candidate for TAF (Tenvir-AF) instead of TDF.

Monitoring schedule: Baseline creatinine, repeat at 3 months, then every 6 months. eGFR drop of >25% or absolute eGFR <60 should trigger reassessment — often a switch to TAF resolves it.

Bone Mineral Density (BMD)

TDF reduces BMD by ~1–2% at the hip and spine in the first year. This is mild, stabilises after the first 12 months, and is fully reversible after stopping. It is below the threshold considered clinically significant for fracture risk in most users.

Higher-risk groups: post-menopausal women, men with hypogonadism, anyone with a history of fragility fracture, long-term steroid users. For these groups TAF is the better choice, and a baseline DEXA scan is reasonable.

Liver Enzymes

Mild transient ALT/AST elevation occurs in a small percentage of users in the first 12 weeks. It almost always resolves without intervention. Persistent ALT >3x upper limit of normal warrants further workup, usually for unrelated causes (alcohol, NAFLD, hepatitis B reactivation if HBV-positive).

Weight and Lipids (TAF-specific)

TAF is associated with modest weight gain (1–3 kg over 96 weeks in DISCOVER trial) and small increases in total cholesterol and triglycerides — TDF tends to be lipid-neutral or slightly lowering. For users with metabolic risk factors, this is the trade-off to weigh against TAF’s renal and bone benefits.

The “Discontinuation” Question: Should You Stop?

Almost no PrEP users actually need to stop because of side effects. In open-label cohorts (US Demo Project, ATN 113, EPIC-NSW), discontinuation rates for side effects sit between 1–3% — and almost all of those are early discontinuation within the first 30 days, before the start-up syndrome has resolved.

The most common reasons to switch (not stop) PrEP:

• eGFR drop on TDF → switch to TAF
• Persistent GI symptoms past week 8 → trial of TAF
• Significant weight gain on TAF → switch back to TDF
• Pregnancy planning → both TDF/FTC and TAF/FTC are continued during pregnancy in current WHO and CDC guidance

What’s NOT a PrEP Side Effect

Research spotlight: A 2019 meta-analysis of 16 PrEP demonstration projects found no association between PrEP and any of the following: depression onset, sexual dysfunction, hair loss, skin rashes outside of rare hypersensitivity reactions, or cardiovascular events. If you develop one of these on PrEP, it’s almost certainly unrelated — don’t stop PrEP for it without other evidence.

What to Watch For: Red-Flag Symptoms

Seek medical assessment promptly for any of these:

• Severe upper abdominal pain with vomiting (rare: lactic acidosis from mitochondrial toxicity — almost never seen with current TDF/TAF dosing but described historically)
• Yellowing of skin or eyes (jaundice — could indicate hepatic dysfunction)
• Rapidly worsening fatigue with reduced urine output (kidney injury)
• Any unexplained rash with fever, mouth ulcers, or facial swelling (drug hypersensitivity — extremely rare with FTC/TDF/TAF but reportable)
• Symptoms of acute HIV seroconversion (fever, lymphadenopathy, rash, sore throat) — this is the one situation where stopping PrEP without medical input is dangerous, because incomplete PrEP coverage can select resistance

Monitoring Schedule: The First Year

For a deeper walkthrough on the STI piece of the monitoring schedule, see our guide on PrEP and STI testing.

Frequently Asked Questions

How long until PrEP fully protects me?

For receptive anal sex, daily oral PrEP reaches maximum protection at 7 days. For receptive vaginal sex and injection drug use, the conservative threshold is 21 days. The CDC also recognises the 2-1-1 on-demand schedule for cis men having sex with men (2 pills 2–24 hours before sex, 1 at 24 hours after, 1 at 48 hours after) — only validated for that subgroup.

Can PrEP make HIV testing fail?

No. The 4th-generation HIV antigen/antibody combo test detects HIV reliably in people on PrEP. The one scenario to be aware of is that PrEP slightly delays seroconversion, so if exposure is suspected, a viral load (HIV RNA PCR) test is added at month 1 — but the standard antibody test still works.

Will my partner know I’m on PrEP from the pill bottle?

The pills look like generic tablets. PrEP discretion is one of the main reasons people order online: discreet plain-envelope packaging arrives without anything indicating contents.

Can I stop PrEP if my situation changes?

Yes — PrEP can be stopped and restarted as life changes. The recommended approach is to take it for 7 days after your last possible exposure (the “tail”), then stop. Restart with the standard 7- or 21-day ramp.

Does alcohol affect PrEP?

Moderate alcohol use has no interaction with PrEP. Heavy alcohol use is associated with PrEP non-adherence (missed doses) rather than a direct drug interaction.

Do I need to take PrEP at the same time every day?

Same-day dosing is what matters; a 6-hour window either way is fine for efficacy. Find a daily anchor — morning coffee, evening tooth-brush — that you don’t skip.

Medical Disclaimer: This content is for general informational purposes and is not a substitute for individual medical advice. PrEP is highly effective at preventing HIV but does not prevent other STIs, and requires baseline and ongoing testing to be used safely. Always work with a qualified healthcare provider for HIV testing, kidney monitoring, and dosing decisions.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.